A triglyceride analog, glycerol-2-palmitoyl-1,3-di-15-(p-iodophenyl)pentadecanoate (DPPG) was synthesized and radiolabeled for evaluation as a potential functional liver scintigraphic agent. Uptake of DPPG was compared in normal, diabetic, tumor-bearing and heparin pretreated rats, revealing differences in uptake and clearance of radioactivity, correlating with hepatic lipase activity of these groups. Similar results were observed by y-camera scintigraphy. Comparing the uptake of DPPG with that of its fatty acid component, 1 S-(p-iodophenyl)pentadecanoic acid (IPPA), revealed that the peak uptake of IPPA in the liver was about half that of DPPG. Based upon these findings, DPPG warrants further study as a hepatic radiodiagnostic agent.
Introduction
Currently the two most frequently used types of liver radiodiagnostics are the 99mTc-labeled sulfur colloid or microaggregated albumin and the 99mTc-labeled iminodiacetic acid (IDA) derivatives. The 99mT~ colloids are phagocytized by the reticuloendothelial (RE) cells of the liver and spleen. Decreased hepatocellular function as in the case of malignant melanoma, portal hypotension or cirrhosis causes more radioactivity to be taken up by the spleen and bone marrow (Jost, 1987) . Since the RE cells are distributed throughout the liver, scintigraphic imaging of these cells provides information about liver size, shape and position. Based on computersimulated images, it has been observed that visual assessment of liver function with Tc-colloid is systematically inaccurate, tending to underestimate poor function and to overestimate good function (Jago et al., 1987) .
On the other hand, the IDA derivatives and I" Irose bengal are taken up by the hepatocyte via an anionic pathway in the same manner as bilirubin. They provide diagnostic information about the patency and the integrity of the biliary drainage system (Chilton and Cowan, 1987) . A decrease in hepatocellular function with an increase in bilirubin level causes a shift from the hepatobiliary excretion of these compounds to renal excretion, due to competition for uptake with bilirubin. Since these compounds are taken up and cleared by hepatocytes without being metabolized in these cells, they do not provide information about the metabolic status of the liver.
Several potential new agents for liver imaging are being developed, such as free fatty acid analogs, 1 5-(p- ['23 I] iodophenyl)-pentadecanoic acid (IPPA) and 17- ['231 ]heptadecanoic acid (IHA). In addition to being developed clinically as cardiac imaging agents, these compounds are also potential hepatic imaging agents since they are taken up by the liver via the anion uptake mechanism and then metabolized by beta oxidation (Machulla and Knust, 1984) . Studies with IHA in humans have shown that uptake in the liver is reduced and the residence time in the liver is increased in alcoholic patients with cirrhosis and also in patients with diabetes (Mertens et al., 1986; Hock et al., 1986) .
The agents described above depend on either phagocytosis into reticuloendothelial cells or uptake into the hepatocytes via the anionic pathway. Alternative means of uptake of radiodiagnostics into the liver utilizing receptor binding have also been tested. Technitium-99m galactosyl-neoglycoalbumin is such an agent. This compound has been shown to bind to a receptor on the cell surface of hepatocytes (Vera et al., 1985) . In addition, radioscintigraphic imaging has also been attempted using '231-labeled very low density lipoprotein (VLDL) for uptake in the liver via the lipoprotein receptor (Huettinger et al., 1984) . It was shown that 32% of the dose was taken up in the liver in the normal rabbit. This uptake was decreased when the low density lipoprotein (LDL) receptors were down-regulated with cholesterol feeding or absent as in the Watanabe-heritable hyperlipidemic rabbit. The difficulty with using such a technique in humans, however, is that the number of liver LDL receptors in the human is much lower than that in rabbits, and the clearance rate of labeled VLDL from the plasma is much slower. In addition, the '23I label on the surface apoproteins is susceptible to deiodination in viuo.
It has been previously demonstrated in this laboratory that intravenous administration of radioiodinated cholesteryl iopanoate solubilized in a detergent vehicle readily associated with plasma lipoproteins in the rat. At 30 min following injection, approx. 31% of the radioactivity accumulated in the liver, and this concentration was seen to increase with time. Upon incorporation of this compound into chylomicron remnants, this uptake was enhanced to 87% present in the liver by 30 min (Damle et al., 1983) . The difficulties with such a preparation are 2-fold. First, the efficiency of incorportation of the radiolabeled compound into the lipoprotein was very low. Secondly, this compound has been shown to be resistant to hydrolysis, so it would provide no information about the metabolic status of the liver.
The rationale for the present study is based upon our current understanding of mammalian lipoprotein metabolism in the liver. The plasma lipoproteins are microscopic vesicles that transport the bulk of nonpolar lipids in the form of a microemulsion, comprised of phospholipids as principal emulsifiers, and amphipathic proteins called apoproteins associated with the surface of these particles. These apoproteins function mainly as ligands for cell-surface receptors. The triglyceride-enriched lipoproteins, chylomicrons (CM) and very low density lipoproteins (VLDL), are synthesized in the intestine and the liver, respectively. Once in the circulation, much of the triglyceride is hydrolyzed by lipoprotein lipase (LPL) bound by heparin sulfate to the endothelial surface of capillaries present in peripheral tissues. The resulting smaller, remnant particle exchanges apoproteins and is then rapidly taken up in the liver by receptormediated endocytosis. Hepatic lipase (HL), an enzyme bound by heparan sulfate to the endothelial cells of the liver, facilitates the uptake of the remnant particle by the liver (Sultan et al., 1990) . In a number of disease states, including alcoholism and diabetes, liver lipoprotein metabolism and HL activity are compromised.
The purpose of this study was to evaluate the potential of glycerol-2-palmitoyl-1,3-di(p-iodo- phenyl)pentadecanoate (DPPG) as a functional hepatic radiodiagnostic agent. This was accomplished by examining its uptake and clearance in normal and disease states. This compound would presumably be treated as an endogenous triglyceride, becoming associated with lipoprotein particles that could be taken up in the liver by specific receptors. Once taken up by the liver, it could become a substrate for liver lipases which would release IPPA for further metabolism and excretion.
Materials and Methods
Female Sprague-Dawley rats, 20&250 g (Charles River, Portage, Mich.) were used in all studies. Rats were housed in a temperature and light-controlled room. Rats had free access to food and water. Diabetes was induced by the injection of streptozotocin (Sigma, St Louis, MO.) iv. in 0.1 M citrate buffer (pH = 4.5) at a dose of 65 mg/kg body wt 3 days prior to administration of compound (Normura et al., 1982) . Another group of rats was innoculated with Walker 256 carcinoma minced in saline (I g tumor/IO mL of saline, I mL injected per rat, > IO6 cells) in the left hindlimb. These animals were used 7-10 days later when the tumor weight averaged 10 g. An additional group of rats was injected with heparin, 100 U/kg body wt i.v. IOmin prior to use (Gibson et al., 1984) .
Compounds
Synthesis and radiolabeling. 15-(p -Iodophenyl)-pentadecanoic acid (IPPA) was obtained commercially (Mara Specialty Chemicals, Philadelphia, Pa). Glycerol-2-palmitoyl-I ,3-di-15-(4_iodophenyl)-pentadecanoate (DPPG) was synthesized by the following method: dicyclohexylcarbodiimide (95 mg, 0.46 mmol) was added to a rapidly stirring solution of 2-monopalmitin (Weichert et al., 1986a) (66mg, 0.20 mmol) , IPPA (186 mg, 0.42 mmol) and a catalytic amount of dimethylaminopyridine (8 mg) in anhydrous CH,Cl, (3 mL) under Nz. The reaction mixture was stirred for 48 h, diluted with CH,Cl, (10 mL) and filtered to remove precipitated dicyclohexylurea. The filtrate was washed successively with 0.5 N HCl (2 x ), saturated aqueous NaHCO, (2 x (Weichert et al., 1986b) for tissue distribution studies and rat scanning studies. In addition, DPPG was radiolabeled with lz31 (Atomic Energy of Canada Limited, Vancouver, B.C.) by the same procedure for the imaging studies in the dog.
Formulation. For administration, IPPA was dissolved in ethanol, then 2% bovine serum albumin (BSA) in water was added to a final ethanol concentration of 10%. DPPG was dissolved in hexane or benzene and Tween 20 (polyoxyethylene sorbitan monolaurate) was added (0.1 mL/mg of compound), and the solvent evaporated under a stream of nitrogen with gentle heating. Physiological saline was added to give a final Tween 20 concentration of l-3%. Any remaining solvent was then evaporated until the solution cleared. Both formulated compounds were extruded through 0.22pm Millex HV filters (Millipore, Bedford, Mass.) prior to administration to animals. Prior to use, the compounds were assayed for radioactivity using a Searle 1185 y-counter (84-86% counting efficiency for 12'I). Radiochemical purity was assessed by thin layer chromatography (TLC) using hexanes : ethyl acetate (5 : 2, v/v) for DPPG and methylene chloride: methanol (95 : 5, v/v) for IPPA. In all cases, greater than 95% of the radioactivity comigrated with the standard.
Tissue distribution. Rats were lightly anesthetized with ether prior to intravenous administration of radiolabeled compound (3.4-18.1 PCi, 0.009-0.075 pmol). At 5,30,60 min or 24 h following administration, the rats were again anesthetized and sacrificed by cardiac puncture. Blood was collected in a vacutainer tube containing heparin. Blood samples were taken for counting and the blood was centrifuged at 800 g for 10 min to obtain plasma. The following organs were removed, rinsed of blood and blotted dry: adrenal, fat, heart, kidney, liver, lung, NMB 19/6--C muscle, ovary, spleen, thyroid and tumor (where applicable). Whole organ weights were taken of liver, spleen and tumor. Large organs were minced with scissors and portions taken for weighing. All tissue samples were weighed in tared cellulose acetate capsules and then assayed for radioactivity. Results are expressed as % administered dose/g tissue and as % administered dose/organ.
Polyacrlyamide gel electrophoresis (PAGE). Plasma samples were analyzed (Narayan, 1975) to determine the association of radioactivity with plasma proteins and lipoproteins. Gels were run and cut as described previously (Counsel1 et al., 1989) .
Lipid extraction. Samples of liver and plasma were homogenized in chloroform : methanol (Folch et al., 1957) . Following homogenization and extraction, the organic phase was analyzed by TLC developed in either hexanes:ethyl acetate (5:2, v/v) for DPPG or methylene chloride: methanol (95 : 5, v/v) for IPPA. TLC results are expressed as the % of total radioactivity comigrating with an unlabeled standard of either free acid or the triglyceride ester.
Biochemical assays. To verify the validity of the various animal models of liver dysfunction utilized in this study, biochemical parameters were measured in rats from all treatment groups. Plasma glucose, triglyceride, protein and SGOT were determined using kits from Sigma (St Louis, MO.), and total cholesterol was determined with a kit from Worthington (Freehold, N.J.).
Heparin-releasable hepatic lipase (HL) was measured using liver homogenates incubated with heparin (Persson and Nilsson-Ehle, 1990 ). These samples were assayed for lipase activity (NilssonEhle and Eckman, 1977) . Results are expressed as nanomoles fatty acid released per hour.
Gamma camera imaging
Rats with ['251]DPPG. Scanning of rats was done with an Ohio Nuclear Mobile Camera, using a high sensitivity-low energy collimator. Rats were sedated with 87 mg/kg ketamine and 13 mg/kg xylazine, i.m., positioned supine on the inverted camera face, then injected with compound (28.8-53.9 PCi, 0.1354.324 pmol). Images were accumulated at intervals out to 90min following administration of compound. Next, animals were injected with 99mTc-microaggregated albumin (Microlite, DuPont-NEN Medical Products, Boston, Mass.) and an image accumulated without shifting the position of the animal. Region-of-interest calculations were later performed by drawing a 15 x 15 pixel square over the 99mTc liver image. Another square was drawn over the heart to measure blood pool activity. The accumulated radioactivity in these regions in all scans was determined to give the percent of total activity and plotted as a function of time.
Dog with ['"I]DPPG.
A female mongrel dog weighing 40 kg was sedated with pentobarbitol for the course of the imaging experiment. The dog 
Results and Discussion
Comparison of DPPG to triolein and tripalmitin as a substrate for HL DPPG was compared to radiolabeled triolein and tripalmitin as a substrate for HL. While triolein had a greater V_ than both tripalmitin and DPPG with values of 34.84, 8.34 and 11.64 nmol/h, respectively, the K,,, values were 370.37 nmol for triolein, 312.50 nmol for tripalmitin and 400 nmol for DPPG. This indicates that DPPG is similar to tripalmitin as a substrate for this enzyme, but is not as good a substrate as triolein. These results appear to agree with the reported 3-to 7-fold increase in activity seen when triolein was used as a substrate compared to tripalmitin for either LPL (Wang et al., 1982) or HL (Masuno and Okuda, 1986) .
Uptake of DPPG and IPPA in untreated rats DPPG administered to untreated rats showed the pattern of uptake seen in Table 1 . The maximum liver uptake was seen at 5 min and corresponded to 52% of the administered dose (Fig. 2) . While the free fatty acid is known to accumulate in the heart, this is not seen with administration of the triglyceride even at 1 or 2 min following administration of the compound (results not shown). The increasing levels of activity seen in the thyroid with time indicate that metabolism and deiodination of the compound are occurring within 30 min following administration.
Similar to DPPG, rats given IPPA showed the greatest level of radioactivity in the liver at 5 min (Fig. 2) . However, this value was approximately one half that seen for DPPG. The levels of radioactivity in the blood following administration of IPPA were similar to that seen for DPPG over the same timecourse (Fig. 2) .
As can be seen in Table 2 , distribution of radioactivity in the various plasma compartments for the rats given IPPA was found to differ significantly from that of rats given DPPG. PAGE analysis revealed most of the radioactivity (75%) was associated with the albumin fraction following administration of IPPA, indicating that most of the radioactivity was still present as the free fatty acid. On the other hand, DPPG administration resulted in greater than 50% of the radioactivity associated with lipoproteins by 5 min. 6.3 * 1.0 6.7 f 2.5 l P < 0.05 vs rats administered DPPG; **P < 0.01 vs rats administered DPPG. tResults expressed as mean percent of total radioactivity applied to gel f SEM. However, an additional 37% of the plasma radioactivity was found in the albumin fraction, suggesting that some hydrolysis of the radiolabeled triglyceride had occurred. With time, the percent radioactivity associated with the albumin band increased. As can be seen in Fig. 3 , analysis of the liver extraction following administration of IPPA revealed that over 66% of the lipid extractable radioactivity was in an esterified form (TLC migration was similar to that of triglyceride and cholesteryl esters) and far exceeded that present as the free acid. It therefore appears that IPPA was rapidly esterified upon entry into the liver. On the other hand, TLC analysis of the radioactivity in the plasma showed the IPPA to be largely present as the free fatty acid. The predominant form of radioactivity in the liver following DPPG administration was the esterified form and these esters gave rise to the free acid with time. Similarly, at early times radioactivity extracted from the plasma of rats receiving DPPG was primarily in the triglyceride fraction. This decreased with time, concurring with the decreased fraction of radioactivity seen migrating with lipoproteins on PAGE analysis.
Comparison of animal models
In order to determine whether the uptake seen in normal animals would be altered in disease states, animal models with disrupted liver function and altered lipoprotein metabolism were studied. These included streptozotocin-induced diabetic rats, rats bearing a Walker 256 tumor implanted in the thigh and rats pretreated with heparin.
Human type I diabetics have been reported to have an increased serum total triglyceride level, especially VLDL triglyceride. This is thought both to be due to increased synthesis of VLDL in the liver and decreased clearance. This decreased clearance is due to decreases in adipose and muscle LPL, causing decreased removal of triglyceride, and an increasing plasma r,,, of the VLDL particle. In addition, diabetic rats have been shown to secrete VLDL lacking apoE and apoC (Berry et al., 1981) . Also, it has been suggested that the apoproteins in diabetics have increased glycosylation, reducing their recognition by receptors.
The presence of tumors in humans and experimental animals has been widely reported to be associated with an increase in plasma triglyceride levels and alterations in the lipoproteins, especially an increase in VLDL. This increase in VLDL triglyceride is thought to be due to decreased lipolysis by LPL. It has been demonstrated that tumor necrosis factor (also known as cachetin) is secreted by activated macrophages, and causes a suppression of LPL activity by decreasing the synthesis of the enzyme in l P < 0.05 vs control rats; l *P < 0.01 vs control rats; ***P < 0.001 vs control rats. tResults expressed as mean Jo SEM. Sn = 5-6 for all groups for measurement of plasma glucose, triglyceride, cholesterol and SGOT.
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adipose tissue (Beutler and Cerami, 1987) . Along with the decrease in LPL activity in adipose, it has been demonstrated that LPL activity was increased in heart and tumor, leading to an overall increase in post-heparin plasma LPL in mice bearing Ehrlich ascites tumor (Balint and Holtzinger, 1984) . This increase in LPL activity in post-heparin plasma, along with a decrease in HL activity, has also been reported in patients with a variety of cancers, including stomach, lung and pancreas, among others, either with or without metastasis to the liver .
Initially, certain physical and biochemical parameters were measured. As can be seen in Table 3 , the weight of the liver was significantly decreased in the Administration of heparin can also alter lipoprotein metabolism as both LPL and HL are bound to the endothelial surface by heparin sulfate. These enzymes are released into the circulation upon treatment with heparin, by non-specifically binding to the polysaccharide. It has been demonstrated that administration of heparin in humans results in a reduction of the total plasma triglyceride, cholesterol and phospholipid. This is due to increased catabolism of triglyceride-rich lipoproteins, decreasing VLDL cholesterol, protein and triglyceride by 50% and increasing LDL and HDL protein and cholesterol levels (Aviram et al., 1986) . Modifications of the lipoprotein patterns seen in normal controls given heparin are similar to those seen in early stage chronic alcoholics (without administration of heparin) (Sass0 et al., 1985) . diabetic rats, while their spleen weight remained similar to control. The tumor-bearing rats showed
In addition to these anatomical changes, differboth an increased liver and spleen weight. This ences in biochemical parameters were observed in increase in liver size in the presence of Walker 256 tumor has been previously noted, however it was also these animal models. The streptozotocin-diabetic rats reported that the weight of the liver expressed as the % of non-tumorous body weight correlated with the tumor weight (Tayek et al., 1986) . There was no difference from control rats in liver or spleen weight for the heparin-treated group as would be expected from an acute treatment. tResults expressed as mean percent of total radioactivity applied to gel k SEM showed a 3-fold increase in plasma glucose over normal animals. This treatment group also had more than double the plasma triglyceride of control, while the heparin-treated group had a 3-fold decrease. The triglyceride levels of the tumor-bearing animals fell over a wide range of values, however, no correlation could be found between plasma triglyceride levels and the size of each animal's tumor. Plasma protein and cholesterol levels were similar for all treatment groups. SGOT levels showed a significant increase in the diabetic group and was more than doubled in tumor-bearing rats, indicating hepatocellular injury. As can be seen in Fig. 4 , there were also significantly lower HL activities of both the streptozotocin-diabetic and tumor-bearing rats when compared with the control animals. These changes in diabetic animals at 3 days after administration of streptozotocin are in agreement with many reports for this animal model (Takanashi ef al., 1987) . Some investigators have reported a moderate hypercholesterolemia in addition to the pronounced hypertriglyceridemia (Redgrave and Snibson, 1977; Brown et al., 1967) . The changes seen in the tumor-bearing animals were also in agreement with the reported hypertriglyceridemia and decreased LPL and HL activity seen with a variety of tumors . In addition, the hypotriglyceridemia present in the heparin-treated rats was as expected (Sass0 et al., 1985) .
Comparison of tissue disposition of DPPG in different animal models
Each of the three treatment groups showed significantly lower uptake of radioactivity in the liver at both 5 and 30min, following administration of DPPG (Fig. 5) . By 60 min the liver values for each group were not significantly different. Both the diabetic and tumored rats showed increased blood levels of radioactivity at 5 min, but all three treatment groups showed significantly decreased blood levels at 30 min. At early time periods, the liver radioactivity in the diabetic group was significantly lower than the blood levels. This is in good agreement with reports of the uptake of radiolabeled triglyceride incorporated into lipoproteins prior to administration to rats (Redgrave and Snibson, 1967; Levy et al., 1985; Bar-On et al., 1984) .
The decreased uptake in the fat, heart and liver of the tumor-bearing rats corresponds to the decreased LPL and HL activity in these animals. Interestingly, the tumor does not take up much of the radioactivity associated with DPPG, although Walker 256 cells have been reported to have LPL activity (Kralovic et al., 1977) . Moreover, it has been reported that TLC plasma VLDL triglyceride removal was decreased in tumor-bearing mice, with a small accumulation in the tumor due to VLDL triglyceride (Lyon et al., 1982) . When the distribution of radioactivity in the plasma was analyzed (Table 4) , the diabetic group showed more radioactivity in the HDL fraction and less in the albumin fraction than control animals at 5 min. This change in PAGE profile was also seen at 30 and 60min. The banding pattern seen in tumorbearing animals was not significantly different from control rats except for an increase in the radioactivity comigrating with LDL. Conversely, heparintreated rats demonstrated a significant decrease in LDL-associated activity at 5 min. Figure 6 illustrates the results obtained from lipid extraction of liver and plasma along with TLC analysis of the extract. At early time periods, all treatment groups displayed decreased levels of extractable activity in the liver. However, the percentage of this extractable radioactivity that migrated with DPPG on TLC was not significantly different for all groups.
Similar analysis of the plasma revealed that the levels of lipid extractable radioactivity were significantly higher for the diabetic and tumored animals at 5 min. Moreover, the predominant form of this radioactivity comigrated with DPPG. However, much less activity remained in the esterified form in the heparintreated animals. In this group there was a decrease in lipid extractable radioactivity with time. position on the camera, removing the liver but leaving the GI tract intact, and rescanning the animal. In addition, if the GI tract was removed and placed on the camera without the rat, the intestine, particularly that section of the duodenum proximal to the stomach was visualized (results not shown). Thus, the radioactivity appears to be clearing via the biliary tree. It is important to note for this comparison, however, that '*'I is a very weak '~-emitter (28 keV) when compared to 99m Tc (140 keV) which accounts for the much sharper image seen with the latter. When a diabetic rat was given DPPG and subjected to y-camera scintigraphy, it demonstrated decreased liver uptake compared to that seen for the untreated rat. In addition, it showed a great deal of activity in the blood pool for the entire scan time. This activity did not clear with time (Fig. 8) .
Gamma camera scintigraphy of['"l]DPPG in the dog
It has been reported that the rat, dog and human have similar levels of hepatic lipase (Jansen and Hulsmann, 1985) . A dog was given DPPG radiolabeled with iz31 in a Tween-saline vehicle. As can be seen in Fig. 9 , uptake of radioactivity occurred in the liver at 25 min post-injection, although radioactivity remained in the blood. With time, the activity in the liver was seen to shift into the gall bladder and gut. This uptake and clearance was graphed in Fig. 10 . The pattern of uptake and clearance was very similar to that seen in the rat, although slightly delayed.
Thus, the radioiodinated triglyceride, DPPG, has been shown here to rapidly become associated with plasma lipoproteins upon administration. This compound is rapidly taken up in the liver, and the associated radioactivity clears the liver with time. In comparing the liver uptake of DPPG with the fatty acid, IPPA, twice as much DPPG is taken up in the liver versus the IPPA. When DPPG was administered to diabetic, tumor-bearing or heparin-treated rats, Fig. 7 . Scans obtained when y-camera scintigraphy was performed on either normal or diabetic rats injected with '2sI-labeled DPPG at either 15 or 90min post-injection. For comparison of liver anatomy and localization, 99"Tc-labeled microaggregated albumin ep"Tc) was given to these same animals at the conclusion of the study and an image was obtained. Fig. 9 . Scans obtained when y-camera scintigraphy was performed on a dog injected with '231-labeled DPGG at 5, 25, 45 and 120min post-injection. For comparison of liver anatomy and localization, 99mTc-labeled microaggregated albumin ( -Tc) was given to this same animal at the conclusion of the study and an image was obtained.
the liver uptake was decreased and the clearance was altered. These results were confirmed by y-camera scintigraphy. Also, while these animals demonstrated alterations in their scintigraphic images with DPPG, 99mTc-microaggregated albumin images in the same animals showed no detectable change in uptake. Moreover, DPPG was evaluated and found to be a substrate for HL. Those animal groups with decreased HL activity also showed a decreased liver uptake of DPPG. In addition, y-camera scintigraphy with DPPG showed a similar pattern of uptake and clearance of radioactivity in the dog. These preliminary findings demonstrate that DPPG is treated in a manner similar to endogenous triglycerides and that a radiolabeled triglyceride analog such as that described here could be used to non-invasively monitor the status of liver lipid metabolism which is disrupted in a number of disease states. Further studies are now in progress to assess the value of DPPG as a functional hepatic imaging agent.
